The performance of Aβ5-X isoforms as novel pharmacodynamic markers of BACE1 inhibition

progressors respectively) (P<0.05). Therewere no differences in composite vascular score, dementia severity (CMMSE and CDR-SOB score), age-related white matter (ARWMC) total score or treatment differences. No differences were noted in APOE status in 6 available data. We found statistically significant increase in GZMB, GZMH, TGFBR3, KLRD1, KIR2DL3 and KIR2DL4 expression (P <0.05) for fast AD-progressors (compared to slow progressors) consistently across 3 time points. Conclusions: Our initial results demonstrate relationship between mRNA levels and fast progression in early AD subjects. This has potential therapeutic implications for the independent role of inflammation and apoptosis in influencing AD progression and we await further confirmation with larger sample analyses.